United Therapeutics (NASDAQ:UTHR) Upgraded to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of United Therapeutics (NASDAQ:UTHR) from a buy rating to a strong-buy rating in a research report report published on Thursday.

Other research analysts also recently issued research reports about the stock. TD Cowen lifted their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Oppenheimer upped their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Wells Fargo & Company raised their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a research report on Thursday, August 1st. Finally, UBS Group raised their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $357.17.

United Therapeutics Price Performance

Shares of UTHR opened at $372.81 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The company has a 50 day moving average price of $349.90 and a 200-day moving average price of $306.93. United Therapeutics has a fifty-two week low of $208.62 and a fifty-two week high of $377.03. The stock has a market capitalization of $16.54 billion, a PE ratio of 17.63, a PEG ratio of 1.30 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.24 EPS. Equities analysts predict that United Therapeutics will post 24.72 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, Director Raymond Dwek sold 5,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the transaction, the director now owns 1,750 shares in the company, valued at $569,362.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $331.32, for a total transaction of $1,192,752.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $43,071.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Raymond Dwek sold 5,000 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the sale, the director now owns 1,750 shares of the company’s stock, valued at $569,362.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 105,830 shares of company stock valued at $36,010,158 over the last ninety days. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of United Therapeutics

Large investors have recently bought and sold shares of the business. Fisher Asset Management LLC grew its position in shares of United Therapeutics by 5.8% in the fourth quarter. Fisher Asset Management LLC now owns 3,828 shares of the biotechnology company’s stock valued at $842,000 after purchasing an additional 209 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in United Therapeutics by 6.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,636 shares of the biotechnology company’s stock valued at $580,000 after buying an additional 164 shares in the last quarter. Rise Advisors LLC acquired a new stake in shares of United Therapeutics in the 1st quarter worth $32,000. Alaska Permanent Fund Corp raised its holdings in shares of United Therapeutics by 263.0% during the 1st quarter. Alaska Permanent Fund Corp now owns 8,172 shares of the biotechnology company’s stock worth $1,877,000 after acquiring an additional 5,921 shares during the period. Finally, Perpetual Ltd purchased a new position in shares of United Therapeutics during the 1st quarter worth $271,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.